Science & discovery

# A new kind of biomarker-directed medicine

We translate deep mechanistic science into therapies matched to the biology of each patient's disease — not just to a tumor type.

Explore the pipeline → Read our publications
The science WEE1 kinase — the cell's checkpoint Cancer cells depend on WEE1 to repair damage and keep dividing. Inhibiting it breaks that safeguard.

Mechanism first

## Understanding the target before we design the drug

Every healthy cell pauses to repair its DNA before dividing. Cancer cells hijack this checkpoint, using WEE1 kinase to survive the stress of rapid, uncontrolled growth.

By selectively inhibiting WEE1, our therapy drives cancer cells past the point of no return — overwhelming their ability to repair and divide — while leaving healthier cells comparatively less affected.

- Oral, once-daily kinase inhibitor
- Selectively targets a central cell-cycle regulator
- Non-chemotherapy mechanism designed for at-home use

Review the translational evidence →

Our principles

## Three principles behind every program

01

### Mechanism-first

We begin with the biology of cell-cycle regulation and identify the patients most likely to respond before a single trial is designed.

02

### Companion diagnostics

A biomarker test is developed alongside the therapy, pairing each patient with the treatment most relevant to their tumor's biology.

03

### Patient-centered design

An oral, once-daily formulation designed to fit into daily life — not a hospital schedule.

How we match patients

## From biomarker to bedside

Our companion diagnostic strategy means the right patients are identified from the very first screen.

1. 01

   ### Biomarker discovery

   Cyclin E1 amplification is validated as a predictor of response across our translational datasets.

2. 02

   ### Screening

   A simple tissue test at trial sites identifies biomarker-positive patients quickly and consistently.

3. 03

   ### Matching

   Eligible patients are matched to the therapy most relevant to the biology driving their disease.

4. 04

   ### Real-world feedback

   Clinical outcomes continuously refine the biomarker strategy and future trial design.

"

> We are advancing the first oral, non-chemotherapy, biomarker-driven approach for Cyclin E1-positive patients — transforming decades of WEE1 research into a novel targeted therapy option.

— Chief Scientific Officer, Zentia Therapeutics
See clinical programs → Talk to our science team